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Abstract 
The increasing use of anticoagulant and antiplatelet therapy for the prevention of 
thromboembolic disease poses a significant challenge to orthopaedic surgeons 
treating elderly patients presenting with proximal femoral fractures. Early surgical 
intervention is known to be beneficial from a clinical perspective and has been 
encouraged in the UK through the introduction of best practice tariffs providing 
increased remuneration for prompt treatment. An understanding of the necessary 
delay to surgery or reversal options for each type of antiplatelet or anticoagulant agent 
is therefore important. A number of professional bodies have recently produced 
guidelines that help clinicians manage these patients during the peri-operative period.  
We review the guidelines relating to antiplatelet and anticoagulant agents during the 
perioperative period with respect to hip fracture surgery. 
Antiplatelet agents should not interfere with timing of surgery, but may affect the choice 
of anaesthetic performed. The action of warfarin should be reversed to expedite 
surgery. Newer direct oral anticoagulants are more problematic and surgical delay 
may be necessary, though reversal agents are becoming available.  
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The last decade has seen a proliferation in the number and diversity of anticoagulant 
and antiplatelet agents and an increase in the indications for their use.. This has 
helped to increase the longevity and reduce the morbidity of patients with vascular 
disease.  An increasing number of this cohort subsequently survive to present to 
orthopaedic services with injuries requiring urgent surgery, most notably those with 
fragility hip fractures. The management of these patients represents a significant 
clinical challenge. Expeditious surgery is indicated both on humanitarian ground and 
also on the basis that it may improve survival [1]. However antiplatelet agents and 
anticoagulants increase the risk attendant to both surgical and anaesthetic 
intervention. Most have no specific antidote (table I). The decision to discontinue such 
medication is not always simple and can place patients at increased risk of 
thromboembolic sequelae.  There is wide variation in clinical practice with regard to 
the peri-operative use of a number of anticoagulant and antiplatelet drugs [2]. Very 
recently, guidelines have been issued by a number of bodies providing clarification on 
the clinical management of patients requiring urgent surgery whilst medicated on 
antiplatelet and anticoagulant agents.  Here we provide a review of these iatrogenic 
coagulopathies and how they relate to management of hip fracture patients. 
 
Aspirin 
Aspirin is widely used in primary and secondary prevention of cardio, cerebro and 
peripheral vascular disease.  It acts by inhibiting the cyclooxygenase enzymes thereby 
preventing the generation of mediators, notably thromboxane, germane to the process 
of platelet aggregation and clot formation [3].  Guidelines from the Scottish 
Intercollegiate Guidelines Network (SIGN), The Association of Anaesthetists of Great 
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Britain and Ireland (AAGBI) and the American College of Chest Physicians (ACCP) 
concur that aspirin should not delay surgery for hip fracture patients [4–6]. The 
guidance however differs as to whether interruption of aspirin therapy is necessary in 
the perioperative period. The AAGBI recommend that aspirin be discontinued except 
in cases of unstable angina or recent/frequent transient ischaemic attack.  The ACCP 
make a similar recommendation in that those with moderate to high risk such as those 
with cardiovascular disease, cerebrovascular disease or diabetes should continue 
aspirin. In those falling into lower risk categories where aspirin is being used for 
primary prevention, consideration should be given to withholding this treatment during 
admission. The basis for the recommendation is unclear, as evidence suggests that 
aspirin does not significantly increase the peri-operative blood loss for hip fracture 
patients [7–10]. 
Aspirin is uncommon amongst antiplatelet and anticoagulant agents in that it has a 
readily available method to reverse its effects if unexpected bleeding occurs. The 
British Society of Haematologists (BSH) in their 2016 guidance on the perioperative 
management of anticoagulant and antiplatelet agents, advises that aspirin antiplatelet 
activity can be reversed with 2 pools of platelets administered 2 hours after the last 
dose of aspirin [11]. 
 
Clopidogrel 
Clopidogrel is a potent antiplatelet agent. It is a pro-drug converted to an active 
metabolite by the liver.  It binds directly to the receptor P2Y12 on platelets inhibiting 
ADP dependent signalling pathways involved in platelet aggregations [3]. There is little 
clinical consensus on the management of patients with hip fracture medicated on 
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clopidogrel [12]. According to SIGN and AAGBI guidelines, surgery should not be 
delayed due to anticoagulation with clopidogrel [4, 5]. Patients medicated on 
clopidogrel represent a high cardiovascular risk cohort. Hence it is advised by the 
AAGBI that clopidogrel therapy not be interrupted during admission for hip fracture [5]. 
This position is corroborated by a recent meta-analysis and large case series showing 
that clopidogrel cessation during admission is associated with an increased risk of 
cardio and cerebrovascular sequelae and does not prevent bleeding complications 
[12, 13]. In addition, the studies found early surgery to be safe with no increase in 
mortality. Doleman and Moppett in their earlier meta-analysis reported similar findings 
[14]. 
Evidence does suggest however that clopidogrel increases peri-operative blood loss 
for hip fracture patients [12]. However it is not clear that this difference is clinically 
significant with regard to patient morbidity or whether it translates into increased 
transfusion requirements.  The meta-analysis of Soo et al suggested that there is no 
increase in transfusion requirements in patients receiving clopidogrel therapy [13]. 
However an earlier meta-analysis looking specifically at patients medicated on 
clopidogrel undergoing early surgery compared to controls suggested a marginal 
increase in risk of transfusion [15]. Clopidogrel therapy increased the odds of 
transfusion by 1.4 with 95% confidence interval of 1.00 to 1.99 compared to those not 
on this therapy [15]. 
Clopidogrel use does have ramifications for spinal anaesthesia. The AAGBI and the 
American Society of Regional Anaesthesia and Pain Medicine guidance recommend 
in general that clopidogrel be discontinued for 7 days prior to the administration of 
spinal anaesthesia [5, 11].  The same guidance suggests that the use of clopidogrel 
6 
 
is not an absolute contraindication for spinal anaesthesia within the 7-day window in 
patients with hip fracture [16].  
In summary, the thrust of evidence suggests that clopidogrel should not be 
discontinued nor surgery delayed for patient medicated on clopidogrel. There is an 
increased bleeding risk and general anaesthesia is preferable to neuraxial 
anaesthesia. 
There is no antidote to clopidogrel.  The efficacy of packed platelets at mitigating its 
antiplatelet effect remains controversial. Studies have shown platelet infusion to 
correct the inhibition of platelet aggregation caused by aspirin but not clopidogrel [3].  
According to the 2016 British Society of Haematologists (BSH) guidance, platelets are 
only effective if clopidogrel is discontinued and administered between 12 and 24 hours 
after the final dose. The number of pools required for reversal is not clear [11].  
Ticagrelor and Prasugrel  
Ticagrelor and Prasugrel both inhibit ADP dependent pathways involved in platelet 
aggregation [3]. Prasugrel is similar to clopidogrel in that its binding to the P2Y12 
receptor is irreversible. However it is more expeditious and effective at achieving 
platelet inhibition. It has a comparable half-life of 7 hours [3]. Hence, in principle, 
platelet infusion is likely to be ineffective at correcting a bleeding diathesis if 
administered shortly after the last dose. Ticagrelor is a reversible inhibitor of ADP 
mediated platelet aggregation. It is a more potent and faster in onset than clopidogrel. 
Ticagrelor is increasingly replacing clopidogrel in the management of acute coronary 
syndromes [17–19]. It may however carry a higher risk of bleeding related 
complications than clopidogrel. Similar to clopidogrel, a platelet infusion does not 
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reverse the effect of ticagrelor [20, 21]. Given the increasing use of ticagrelor, 
developers AstraZeneca are in the process of developing an antidote [22]. 
There are no explicit guidelines for the newer antiplatelet agents. The mode of action 
suggests patients with hip fracture should be managed in a similar fashion to those on 
clopidogrel.  
Phosphodiesterase inhibitors 
Dipyridamole and Cilostazol are antiplatelet agents that inhibit platelet aggregation by 
inhibiting phosphodiesterase and blocking the reuptake of adenosine by platelets. 
Dipyridamole is used as an adjunct to warfarin for the prevention of thromboembolism 
associated with metallic cardiac valves. It is also an option, often in combination with 
aspirin, for the secondary prevention of thrombosis in patients who have sustained a 
transient ischaemic attack [23]. Cilostazol is a second line drug for the treatment of 
vascular claudication. There are no specific guidelines on the management of fracture 
neck of femur patients receiving these drugs, however the antiplatelet effect of these 
agents is relatively weak and therefore their use should not delay surgery [24]. 
Dual Antiplatelet therapy (DAT) 
This is commonly indicated in patients who represent high cerebrovascular and 
cardiovascular risk. Aspirin and ticagrelor, clopidogrel, prasugrel or dipyridamole are 
the most common combinations. Evidence suggests DAT is associated with an 
increased bleeding risk following hip fracture surgery. A modest-sized study however 
found surgery in fracture patients on DAT (clopidogrel and aspirin) to be safe [9].  The 
BSH recommend the use of tranexamic acid to control the bleeding effects associated 
with DAT.  
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Those patients who have undergone recent cardiovascular stenting are at particularly 
high risk of thromboembolic phenomena. Such patients are frequently on DAT. The 
ACCP and American College of Cardiology (ACC) guidelines suggest that these 
agents should be continued if possible as interruption to therapy poses a risk of stent 
thrombosis. If there is a need to discontinue an agent it should be the P2Y12 inhibitor 
that is stopped [25]. The risk of stent thrombosis is highest within the first 30 days for 
bare metal cardiac stents or 6 months for drug eluting stents and dual therapy should 
be continued during this time period. In instances where there is a very high and 
undesirable bleeding risk for a patient with dual therapy but cessation of antiplatelet 
agents poses a high-risk, the P2Y12 inhibitor can be discontinued and "bridging cover" 
provided using enteral platelet glycoprotein IIb/IIIa receptor inhibitors [3]. These agents 
have a short half-life and can be rapidly discontinued and restarted post-operatively.  
Direct Oral Anti-Coagulants 
The direct oral anticoagulants (DOACs) are increasingly being used to replace 
warfarin and have a wide therapeutic repertoire. There are no explicit guidelines as to 
the management strategy for patients requiring urgent hip fracture surgery, medicated 
on DOACS. More detailed guidance is available with respect to elective surgery. Given 
that until very recently there were no readily available reversal agents, surgeons are 
bound to some degree by the recommendations for elective surgery. Lai et al in their 
review advocated a minimum delay of 12 hours, but preferably 24 hours, from the last 
dose of DOAC prior to surgery [26]. The BSH advocates a delay of 48 hours before 
elective surgery with a major risk of bleeding in those with normal renal function [11].  
Surgery can only be performed when it is safe to do so.  The increasing use of DOACs 
will have tangible ramifications for the remuneration hospitals receive for hip fracture 
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surgery. The National Health Service Best Practice Tariff financial reward of £1335 
per patient for hip fracture is only paid if their treatment meets certain criteria [27]. A 
major criterion is surgery within 48 hours of admission. There is no exemption for 
patients medicated on anticoagulants.  The use of DOACs may make achieving this 
target increasingly difficult. 
 
Rivaroxaban , Apixaban & Edoxaban 
Rivaroxaban, apixaban and edoxaban are all direct inhibitors of factor Xa. The BSH 
recommend discontinuing these agents for 48 hours prior to elective surgery with high 
bleeding risk. In those with renal impairment (creatinine clearance <30ml/min) the 
period should be extended to 72 hours. According to the BSH, all agents should be 
re-introduced at 48 hours after surgery with thromboprophylaxis post-operatively as 
normal until full re-introduction of the DOAC [11]. There is no explicit recommendation 
from BSH for hip fracture surgery. The manufacturer’s recommendations differ 
somewhat for rivaroxaban and edoxaban compared to those from BSH, 
recommending cessation for 24 hours prior to surgery [28, 29]. The manufacturers for 
all 3 agents advise reintroduction as soon as possible after the procedure (e.g. 6-10 
hours for Rivaroxaban) with no specific 48 hour stipulation [25, 26, 30]. 
There are implications for anaesthesia. According to the AAGBI guidance neuraxial 
blockade should be avoided for 24-48 hours following the last dose of apixaban and 
48 hours for rivaroxaban [5]. If surgery is required before this, general anaesthesia is 
indicated.  
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Dabigatran  
This is a direct thrombin inhibitor. A normal thrombin time excludes any significant 
dabigatran activity. The BSH guidelines for elective surgery recommend that 
dabigatran treatment should be interrupted for 48 hours. However the interval rises 
with increasing renal impairment to 96 hours for those the creatinine clearance less 
than 50ml/hr [11]. The BSH, as with the other DOACs, recommends that dabigatran 
be reintroduced at 48 hours after surgery [11]. 
The manufacturer advise that in cases of subacute surgery, dabigatran should be 
stopped for at least 12 hours from the last dose before surgery, and introduced as 
soon as possible post procedure. The manufacturer recognises that renal impairment 
can cause significant delay in clearance. In those with a creatinine clearance of less 
than 50ml/hr, it is recommended that dabigatran be discontinued for 4 days prior to 
high risk elective surgery. 
AAGBI guidelines for neuraxial blockade in the context of dabigatran are similar to 
those for major surgery. In those with creatinine clearance of greater than 80ml/hr, a 
48 hour window is required. In those clearance values between 80 and 50, this rises 
to 72 hours and finally 96 hours, where creatinine clearance is less than 50ml/hr [5]. 
Clearly a delay of 4 days is unacceptably long for a patient with hip fracture. Hence in 
patients with renal failure for whom hip fracture surgery is necessary specific antidotes 
to the DOACs may be indicated. 
Antidotes to DOACs 
Specific antidotes for DOACs are starting to emerge: 
Idarucizumab 
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Idarucizumab is the first specific antidote to a DOAC to be licensed in the UK and US. 
The agent, which is a humanised monoclonal antibody, binds to and reverses the 
effects of dabigatran. The uncontrolled REVERSE AD trial involving 90 patients 
medicated with dabigatran who had uncontrolled haemorrhage or need for emergency 
surgery showed that idarucizumab completely reversed the elevated dilute thrombin 
time and the ecarin clotting time in 88-98% of patients, with an effect that was evident 
in minutes after delivery of the infusion [31]. The drug is relatively expensive with a 5g 
dose costing £2400 but BSH advocate its use where emergency surgery is required 
[11, 32].  
Andexanet 
Andexanet is a drug that is under development but is not yet licenced for use in either 
the UK or US. It acts as a decoy target for rivaroxaban, apixaban and edoxaban. It has 
proven efficacy at reversing the activity of these DOAC in patients with bleeding 
episodes [33]. There are a number of unresolved issues including: the effect of the 
timing of the last dose of a DOAC on the dose required of andexanet, the duration of 
a continuous infusion to provide adequate therapy, variations in dose required 
depending on DOAC and the timing of reinstituting anticoagulation after treatment [34]. 
The BSH have endorsed the use of andexanet for the reversal of the anticoagulation 
within emergency surgery when it becomes available [11]. 
Tranexamic Acid 
The BSH recommend the use of tranexamic acid to mitigate the bleeding effect of both 
antiplatelets and DOACs. It stabilises clots by inhibiting the activation of plasminogen 
to plasmin.  The latter is responsible for clot degradation by means of targeting fibrin, 
a key component of the clot. Tranexamic acid is thus an antifibrinolytic [35]. However 
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the British National Formulary and manufacturer summary product characteristics 
state its use is contraindicated in those with a history of venous or arterial thrombosis 
[36].  This would thus include those receiving anti-platelets and DOAC therapy. 
However, a recent large systematic review showed that the use of tranexamic acid in 
hip fracture surgery reduced transfusion requirements by 46% (95% confidence 
interval 35% to 85%) and increased post-operative haemoglobin levels. There was no 
reported increase in thrombotic events, but the authors state the quality of the 
evidence was low with respect to this finding [37]. Studies in elective orthopaedic 
surgery have not shown an increased thrombosis risk with the use of tranexamic acid 
[38].   
Warfarin 
It is estimated that 5% of hip fracture patient are medicated on warfarin [5] and 
warfarinised patients may endure delays to surgery. A recent large study found that 
patients medicated on warfarin were only a fifth as likely to undergo surgery within 36 
hours even after adjustment for potential confounders, when compared those not 
receiving this medication [39]. Warfarin inhibits vitamin K dependent-generation of 
factors II, VII, IX and X. Its action is effectively reversed by vitamin K. Its anticoagulant 
action is monitored using the INR. The target range for surgery is less than 1.5 for 
spinal anaesthesia [11].  Reversal of warfarin activity is recommended for hip fracture 
surgery in the SIGN guidelines [4]. 
Beriplex is an alternative, but expensive, antidote compared to vitamin K.  The mean 
cost of a reversal dose is £550 [40] compared to £0.19 for 5mg of intravenous vitamin 
K [41]. However it reverses the anticoagulant effect of warfarin within 30 minutes and 
lasts up to 6 hours [42]. It may be administered in conjunction with vitamin K (5mg) to 
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avoid rebound rises in INR once the effect of PCC is extinguished [43]. As Beriplex is 
much more expeditious in effect than vitamin K it may prevent the delays often seen 
when vitamin K is used to reverse the effect of warfarinisation.  
The BSH advocate that for certain high risk patients, once the INR becomes 
subtherapeutic, short-acting bridging anticoagulation is required in the form of low 
molecular weight heparin or intravenous unfractionated heparin [11]. Such patients 
include 
• Those with metallic heart valves.  
• Patients with a history of deep vein thrombosis or pulmonary embolism within the 
3 months preceding a hip fracture and patients who have developed 
thromboembolic disease while already on anticoagulant therapy.  
• Those with atrial fibrillation who have suffered stroke or a transient ischaemic 
attack within 3 months of presentation with a hip fracture. 
For patients with atrial fibrillation the BSH recommend that risk stratification should be 
performed according to the CHA2DS2VASC score [44]. A score of 4 or greater is 
indicative of high thromboembolic risk and consideration should be given to bridging 
anticoagulation in this group [11]. This advice was based on the study by Douketis et 
al. In this large prospective randomised controlled trial of surgical patients on warfarin 
for atrial fibrillation, it was found that bridging anticoagulation did not reduce the risk 
of thromboembolic disease, but did increase bleeding complications compared to 
those who were not given any bridging anticoagulation [45]. However, the study 
included very few patients with a CHA2DS2VASC score above 4, therefore bridging 
continues to be recommended for these patients. 
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Antithrombotics and anticoagulants have improved the survival of patients at high risk 
of thromboembolic diseases. Surgeons need to be conversant with the gamut of 
agents to ensure that surgery is performed safely and expeditiously in this vulnerable 
cohort. The timing of the last dose of any anticoagulant or antithrombotic agent is 
increasingly an important component of the clinical history of hip fracture patients. 
There is merit in the formulation of local guidelines in conjunction with haematologists 
and transfusion services regarding the management of hip fracture patients medicated 
on antithrombotic and anticoagulant agents.  We would advocate incorporation of 
these guidelines into hip fracture clerking proformas to help the multidisciplinary team 
manage these patients efficiently and effectively. 
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Table I: Summary of anticoagulant and antiplatelet agents in common use and 
relevant guidance on perioperative management
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Agent Target Pharmacokinetics Diagnostic test Agents to restore 
haemostasis 
Hip fracture surgery guidance 
Aspirin 
(Acetylsalicylic 
acid, active 
metabolite 
salicylic acid) 
Platelet 
aggregation 
 
Cyclooxygenase 
irreversible 
inhibitor 
Elimination half-
life 20 minutes 
(Permanent 
inactivation of 
platelets occurs 
meaning clinical 
effects reverse 
with natural 
turnover of 
platelets (approx. 
10%/day) 
Platelet function tests 
Closure time assay 
Bleeding time 
Viscoelastometry 
Platelet aggregometry 
Flow cytometry 
Platelets (2 units) 
minimum 2 hours after last 
dose of drug. 
DDAVP 
Delay of surgery or reversal rarely 
necessary. (SIGN, AAGBI, ACCP) 
Clopidogrel Platelet 
aggregation 
 
P2Y12 receptor 
irreversible 
inhibitor 
Elimination half 
life 6 hours. 
Platelet function tests Platelets (no consensus on 
dose) minimum 12-24 
hours after the last dose. 
Hip fracture surgery delay not necessary 
(BSH). Spinal anaesthesia not 
contraindicated in hip fracture patients 
who have received the drug during the 
preceding 7 days, though general 
anaesthesia may be preferable. (AAGBI). 
General anaesthetic should be performed if 
on dual antiplatelet therapy (SIGN). 
Ticagrelor 
 
 
Platelet 
aggregation 
 
P2Y12 reversible 
inhibitor 
Elimination half 
life: parent drug 
approx. 7 hours, 
active metabolite 
approx. 9 hours 
Platelet function tests Platelets  No specific guidance. SIGN advise that anti-
platelet therapy should not delay surgery. 
Prasugrel Platelet 
aggregation 
 
Elimination half 
life: active 
metabolite 
approx. 7 hours 
Platelet function tests Platelets  No specific guidance. SIGN advise that anti-
platelet therapy should not delay surgery. 
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P2Y12 reversible 
inhibitor 
Dipyridamole Platelet 
aggregation 
 
Dose dependent 
inhibition of 
adenosine uptake 
into platelets. 
Phosphodiesterase 
inhibitor. 
Elimination half 
life: 2 phase 
model. Initial 
decline 
40minutes, 
terminal decline 
10 hours. 
Platelet function tests Platelets No specific guidance. SIGN advise that anti-
platelet therapy should not delay surgery. 
Cilostazol Platelet 
aggregation 
 
Dose dependent 
inhibition of 
adenosine uptake 
into platelets. 
Phosphodiesterase 
inhibitor. 
Elimination half-
life: 11-13 hours 
Platelet function tests Platelets No specific guidance. SIGN advise that anti-
platelet therapy should not delay surgery. 
Rivaroxaban Factor Xa inhibitor Elimination half 
life: 5-9 hours, 
longer in the 
elderly (11-13 
hours). 
PT and APTT may be 
abnormal. 
Factor Xa assays 
Andexanet and Aripazine 
under investigation as a 
reversal agent. 
 
In case of severe bleeding 
consider prothrombin 
complex concentrate. 
Manufacturer advises 24 hour surgical 
delay after last dose. BSH advise to delay 
surgery until 48 hours after last dose and 
72 hours in renal impairment (BSH planned 
surgery guideline). Avoid neuraxial block 
for 48 hours after last dose (AAGBI) 
Apixaban Factor Xa inhibitor Elimination half-
life: 12 hours 
PT and APTT may be 
abnormal. 
Factor Xa assays  
Andexanet and Aripazine 
under investigation as a 
reversal agent. 
BSH advise to delay surgery until 48 hours 
after last dose and 72 hours in renal 
impairment (BSH planned surgery 
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In case of severe bleeding 
consider prothrombin 
complex concentrate. 
guideline). Avoid neuraxial block for 24 
hours after last dose (AAGBI) 
Edoxaban Factor Xa inhibitor Elimination half-
life: 10-14 hours 
PT and APTT may be 
abnormal. 
Factor Xa assays 
Andexanet and Aripazine 
under investigation as a 
reversal agent. 
 
In case of severe bleeding 
consider prothrombin 
complex concentrate. 
BSH advise to delay surgery until 48 hours 
after last dose and 72 hours in renal 
impairment (BSH planned surgery 
guideline). Avoid neuraxial block for 24 
hours after last dose (AAGBI) 
Dabigatran Thrombin inhibitor Elimination half-
life: 12-17 hours, 
longer in renal 
impairment (28 
hours in severe 
renal impairment) 
APTT and Thrombin 
time increased. 
Ecarin clotting time. 
Idarucizumab BSH advise to delay surgery until 48 hours 
after last dose and 96 hours in severe renal 
impairment (BSH planned surgery 
guideline). Avoid neuraxial block for 48 
hours after last dose with normal renal 
function, increased to 96 hours with severe 
renal impairment (AAGBI) 
Warfarin Inhibits Vitamin K 
dependent 
synthesis of 
factors II, VII, IX 
and X 
Elimination half-
life: 20-60 hours 
INR 5mg intravenous 
Phytomenadione  (Vitamin 
K1) and delay surgery 6-8 
hours. Lower doses for 
partial reversal. 
Prothrombin complex 
concentrate for more 
urgent reversal.  
SIGN recommend partial reversal of 
warfarin with 1-2.5mg intravenous or oral 
phytomenadione. 
BSH advise 5 mg of intravenous 
phytomenadione or 25-50µg/Kg of Beriplex 
(prothrombin complex concentrate) 
